Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO]

NCT00416429 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT00416429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00416429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO]
Lead sponsor
Centre Leon Berard
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
February 28, 2005
Enrollment
456 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer